Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists
N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high throughput screen (HTS) of a sub-set of the AstraZeneca compound bank. As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist p...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
American Chemical Society
2017
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/45586/ |